2. Academic Validation
  3. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

  • Biomed Pharmacother. 2021 Dec:144:112347. doi: 10.1016/j.biopha.2021.112347.
Sonia Solanes-Casado 1,  Arancha Cebrián 2,  María Rodríguez-Remírez 3,  Ignacio Mahíllo 4,  Laura García-García 1,  Anxo Río-Vilariño 1,  Natalia Baños 1,  Guillermo de Cárcer 5,  Ana Monfort-Vengut 5,  Víctor Castellano 6,  Maria Jesús Fernández-Aceñero 7,  Jesús García-Foncillas 8,  Laura Del Puerto-Nevado 9
Affiliations

Affiliations

  • 1 Translational Oncology Division, Oncohealth Institute, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • 2 Translational Oncology Division, Oncohealth Institute, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain. Electronic address: [email protected].
  • 3 Department of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain.
  • 4 Department of Statistics, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain.
  • 5 Cell Cycle & Cancer Biomarkers Group, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm) CSIC-UAM, 28029 Madrid, Spain.
  • 6 Department of Pathology, Fundación Jiménez Díaz University Hospital (UAM), Madrid, Spain.
  • 7 Department of Pathology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • 8 Translational Oncology Division, Oncohealth Institute, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain. Electronic address: [email protected].
  • 9 Translational Oncology Division, Oncohealth Institute, IIS - Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain. Electronic address: [email protected].
PMID: 34700228 DOI: 10.1016/j.biopha.2021.112347
Abstract

New therapeutic targets are revolutionizing colorectal Cancer clinical management, opening new horizons in metastatic patients' outcome. Polo Like Kinase1 (PLK1) inhibitors have high potential as antitumoral agents, however, the emergence of drug resistance is a major challenge for their use in clinical practice. Overcoming this challenge represents a hot topic in current drug discovery research. BI2536-resistant colorectal Cancer cell lines HT29R, RKOR, SW837R and HCT116R, were generated in vitro and validated by IG50 assays and xenografts models by the T/C ratio. Exons 1 and 2 of PLK1 gene were sequenced by Sanger method. Axl pathway, Epithelial-to-Mesenchymal transition (EMT) and Multidrug Resistance (MDR1) were studied by qPCR and western blot in resistant cells. Simvastatin as a re-sensitizer drug was tested in vitro and the drug combination strategies were validated in vitro and in vivo. PLK1 gene mutation R136G was found for RKOR. Axl pathway trough TWIST1 transcription factor was identified as one of the mechanisms involved in HT29R, SW837R and HCT116R lines, inducing EMT and upregulation of MDR1. Simvastatin was able to impair the mechanisms activated by adaptive resistance and its combination with BI2536 re-sensitized resistant cells in vitro and in vivo. Targeting the mevalonate pathway contributes to re-sensitizing BI2536-resistant cells in vitro and in vivo, raising as a new strategy for the clinical management of PLK1 inhibitors.

Keywords

BI2536; Colorectal cancer (CRC); Drug resistance; Polo-Like Kinase 1 (PLK1); Re-sensitization; Simvastatin.

Figures
Products